• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Stock

Elon Musk’s Neuralink raises $650 million in fresh capital

by June 3, 2025
written by June 3, 2025

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
House Dems urge GOP to condemn DHS for handcuffing Rep Nadler staffer, order Noem to testify
next post
Uber delivery chief Gore-Coty is leaving after almost 13 years at ride-hailing company

related articles

L.A. County sues Roblox, alleges platform makes it...

February 21, 2026

CFTC chief sides with prediction markets over state...

February 19, 2026

Warner Bros. Discovery reopens talks with Paramount

February 18, 2026

Justice Department’s antitrust chief says she’s leaving, effective...

February 14, 2026

Cardi B’s cameo in Bad Bunny’s Super Bowl...

February 13, 2026

Retail operator of outdoor sportswear pioneer Eddie Bauer...

February 12, 2026

Landmark trial accusing social media companies of addicting...

February 11, 2026

Trump administration alleges Nike discriminated against white workers

February 5, 2026

The architect of Amazon’s supply chain on running...

February 5, 2026

Elon Musk’s SpaceX acquires xAI

February 3, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • US envoy Witkoff says high-level Miami talks focused on ‘unified Gazan authority’ as Israel ceasefire advances

    December 20, 2025
  • Inside Trump’s urgent meeting with House GOP to pass the ‘big, beautiful bill’

    May 20, 2025
  • Business is good in ‘Vacationland.’ It would be even better with more housing.

    August 5, 2024
  • Why Zuckerberg killed fact-checking as he keeps cozying up to Trump

    January 8, 2025
  • As Epstein-linked appointment sparks backlash, UK PM Starmer faces party revolt amid resignation calls

    February 9, 2026

Popular Posts

  • 1

    District judges’ orders blocking Trump agenda face hearing in top Senate committee

    April 2, 2025
  • 2

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024

Categories

  • Economy (829)
  • Editor's Pick (8,131)
  • Investing (1,049)
  • Stock (979)

Latest Posts

  • Hunter Biden’s pardon sets troubling precedent, risks politicizing Justice Department, critics say

    December 3, 2024
  • DOJ seizes record $225 million in crypto tied to global ‘pig butchering’ scams

    June 19, 2025
  • GOP reaches key 50-vote threshold for Trump-backed voter ID bill as Senate fight looms

    February 17, 2026

Recent Posts

  • Hamas ‘hardens’ stance in ceasefire talks as Netanyahu recalls negotiation team

    July 24, 2025
  • Dem, GOP insiders both see major opportunity after Biden’s first solo presser in months

    July 13, 2024
  • Johnson demands NARA turn over records related to Biden’s mental ‘decline’ amid Senate probe of ‘cover-up’

    July 17, 2025

Editor’s Pick

  • Trump, Zelenskyy to meet for key deal as NATO allies, Russia wait, watch

    February 28, 2025
  • GOP lawmaker accuses Jack Smith of ‘spying’ on Congress at tense House hearing over Trump probe

    January 22, 2026
  • Amazon expects to cut corporate jobs as it relies more on AI

    June 18, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock